Why can't a trial separate weight loss from direct effects?

The participants who received the drug are the participants who lost weight. They are collinear, and no post-hoc statistics can disentangle them.

Are direct effects plausible?

Yes. GLP-1 receptors are described in cardiovascular and renal tissue, and effects on inflammation and haemodynamics have been proposed. Plausible is not demonstrated.

GLP-1 & Incretin Science

The Attribution Problem Running Through Every Indication

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Cardiovascular, renal and hepatic benefits reported for incretin agonists all occur in participants who also lost substantial weight. Whether the benefit follows from weight reduction or from direct tissue effects cannot be resolved within a trial where both happen together.

Key facts

The problem: Weight and organ benefit are collinear
Affects: SELECT, FLOW, ESSENCE alike
One approach: Subgroups by concomitant therapy
FLOW example: With vs without SGLT2 inhibitor
Another approach: Compare against non-incretin weight loss
Status: Genuinely unresolved

Why this is not a pedantic question

It determines what the drug is. If organ benefits follow from weight reduction, then any intervention producing equivalent weight loss should produce equivalent benefit, and the incretin is one route among several. If there are direct effects, the compound is doing something bariatric surgery or diet cannot replicate, and the class occupies a different position entirely.

Why a single trial cannot settle it

Collinearity. In any trial of these compounds, the participants who received the drug are the participants who lost weight — the two are not independent variables and cannot be disentangled by statistics applied afterwards. This is a structural feature of the design, not a shortcoming of the analysis.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

The mechanistic case for direct effects

GLP-1 receptors are not confined to pancreas and brain. They are described in cardiovascular tissue, kidney and elsewhere, and incretin signalling has been linked to inflammatory and haemodynamic changes independent of glycaemia. That makes direct effects biologically plausible rather than speculative — plausible is not the same as demonstrated.

How trial teams probe it anyway

By looking at subgroups where an alternative explanation is already saturated. The FLOW analysis of participants with and without concomitant SGLT2 inhibitor use is a good example: if the benefit merely duplicated an established renal mechanism, it should shrink where that mechanism is already engaged. Persistence of effect argues for something additional.

What would actually resolve it

A trial comparing an incretin against a different intervention producing matched weight loss, with organ outcomes as endpoints. That is expensive, slow, ethically complicated and largely has not been done — which is why the question remains open despite being the most important one about this class.

How to read claims in the meantime

Treat organ benefit as demonstrated for the compound as administered, and treat the mechanism as unresolved. Those are compatible positions. A claim that a drug protects the kidney independent of weight loss requires evidence the current trials cannot supply.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Why can't a trial separate weight loss from direct effects?: The participants who received the drug are the participants who lost weight. They are collinear, and no post-hoc statistics can disentangle them.
Are direct effects plausible?: Yes. GLP-1 receptors are described in cardiovascular and renal tissue, and effects on inflammation and haemodynamics have been proposed. Plausible is not demonstrated.
What would settle it?: A trial against a different intervention producing matched weight loss, with organ outcomes as endpoints. That has largely not been done.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum